PR Newswire
— Conference Call Scheduled for
5:00 p.m. ET
—
SAN DIEGO
,
July 28, 2022
/PRNewswire/ — Evofem Biosciences, Inc., (Nasdaq: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the second quarter ended June 30, 2022 as follows:
|
|
|
|
|
|
|
|
|
|
related slide presentation: |
|
Please connect to the webcast at least 15 minutes prior to the start of the call to download any software that may be required. If participating by phone, please dial in approximately 15 minutes prior to the start of the call.
About Evofem Biosciences
Evofem Biosciences, Inc., (Nasdaq: EVFM) is developing and commercializing innovative products to address unmet needs in women’s sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from chlamydia and gonorrhea. The Company’s first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. The Company expects to report top-line data this fall from its registrational Phase 3 EVOGUARD clinical trial evaluating Phexxi for two potential new indications – prevention of chlamydia and prevention of gonorrhea in women. Learn more at
phexxi.com
and
evofem.com
.
Phexxi® is a registered trademark of Evofem Biosciences, Inc.
Investor Relations Contact
Amy Raskopf
Evofem Biosciences, Inc.
(917) 673-5775
View original content to download multimedia:
https://www.prnewswire.com/news-releases/evofem-biosciences-to-report-second-quarter-2022-results-and-provide-corporate-update-on-thursday-august-4-2022-301595132.html
SOURCE Evofem Biosciences, Inc.
